Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine
نویسندگان
چکیده
منابع مشابه
Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
BACKGROUND Large clinical studies assessing long-term adefovir dipivoxil salvage monotherapy in patients with lamivudine-resistant chronic hepatitis B (CHB) are lacking, particularly in patients positive for hepatitis B e antigen (HBeAg). We assessed the efficacy and resistance profile of adefovir dipivoxil monotherapy for up to 5 years in a large cohort of Korean patients with lamivudine-resis...
متن کاملTwo years efficiency of lamivudine and adefovir dipivoxil combined therapy in chronic hepatitis B patients.
BACKGROUND Lamivudine (LAM) and adefovir (ADV) are widely used in most Asian countries, though monotherapy is associated with the occurrence of resistance. AIM To evaluate the efficiency of LAM and ADV combined treatment of chronic hepatitis B patients with compensated cirrhosis. PATIENTS AND METHODS 206 eligible Chinese patients were randomly assigned in a 1:1 ratio to receive either LAM o...
متن کاملA randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol
OBJECTIVE To evaluate the efficacy and safety profiles of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) treated with adefovir dipivoxil (ADV) or ADV plus bicyclol, and to optimize the treatment strategy for CHB patients. PATIENTS AND METHODS A total of 250 patients with HBeAg-positive CHB were randomized to ADV plus bicyclol combination group and ADV monothera...
متن کاملAdefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
BACKGROUND In preclinical and phase 2 studies, adefovir dipivoxil demonstrated potent activity against hepatitis B virus (HBV), including lamivudine-resistant strains. METHODS We randomly assigned 515 patients with chronic hepatitis B who were positive for hepatitis B e antigen (HBeAg) to receive 10 mg of adefovir dipivoxil (172 patients), 30 mg of adefovir dipivoxil (173), or placebo (170) d...
متن کاملSerum levels of surface large envelope proteins: prognostic markers for hepatitis B e antigen-negative patients with adefovir dipivoxil treatment.
BACKGROUND The present investigation was undertaken to evaluate the prognostic role of pretreatment serum hepatitis B virus (HBV) surface large envelope protein (LHBs) levels in the curative effects after 48-week adefovir dipivoxil (ADV) treatment. METHODS A total of 128 patients received ADV once daily for 48 weeks. Serum levels of LHBs were detected by ELISA. Real-time quantitative PCR was ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Alimentary Pharmacology & Therapeutics
سال: 2007
ISSN: 0269-2813,1365-2036
DOI: 10.1111/j.1365-2036.2007.03567.x